Literature DB >> 3098272

Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro.

M Khor, D B Lowrie, D A Mitchison.   

Abstract

The effect of recombinant murine interferon-gamma (IFN-gamma) on the growth of Listeria monocytogenes for 4 h and Mycobacterium microti for up to 3 days in monolayers of peritoneal macrophages from BALB/c mice was examined by serial viable counts of cell-associated bacteria. Macrophages pretreated with 10 u IFN-gamma per ml were bacteriostatic and with 100 u or 1000 u per ml were bactericidal against L. monocytogenes. Addition of IFN-gamma 3 days before infection caused monolayers to be bactericidal against M. microti mainly during the first 15 min after infection. This was just evident with 10 u IFN-gamma per ml and greater with 100 u or 1000 u per ml. If IFN-gamma was added when phagocytosis of M. microti was complete, about 2 h after infection, its action was only bacteriostatic, the viable counts remaining stationary while those of unexposed monolayers increased. IFN-gamma 100 u per ml added before infection did not alter the bactericidal activity of rifampicin 10 mg/l, nor did it alter the killing curves for isoniazid 1 mg/l or for rifampicin 10 mg/l if added after completion of phagocytosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3098272      PMCID: PMC2012967     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  14 in total

1.  Lymphocyte reactivity during spaceflight.

Authors:  A Cogoli; A Tschopp
Journal:  Immunol Today       Date:  1985-01

2.  A simple, rapid, and sensitive DNA assay procedure.

Authors:  C Labarca; K Paigen
Journal:  Anal Biochem       Date:  1980-03-01       Impact factor: 3.365

3.  Gamma-interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular Chlamydia psittaci replication.

Authors:  C D Rothermel; B Y Rubin; H W Murray
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

4.  Benzylpenicillin transport and subcellular distribution in mouse peritoneal macrophage monolayers.

Authors:  D B Lowrie; T J Peters; A Scoging
Journal:  Biochem Pharmacol       Date:  1982-02-01       Impact factor: 5.858

5.  Killing of Mycobacterium microti by immunologically activated macrophages.

Authors:  L Walker; D B Lowrie
Journal:  Nature       Date:  1981-09-03       Impact factor: 49.962

6.  Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon.

Authors:  A F Kiderlen; S H Kaufmann; M L Lohmann-Matthes
Journal:  Eur J Immunol       Date:  1984-10       Impact factor: 5.532

7.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

8.  Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1981-04

9.  Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing.

Authors:  J L Pace; S W Russell; B A Torres; H M Johnson; P W Gray
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

10.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  9 in total

1.  Characterization of T cells that confer a high degree of protective immunity against tuberculosis in mice after vaccination with tumor cells expressing mycobacterial hsp65.

Authors:  C L Silva; M F Silva; R C Pietro; D B Lowrie
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 2.  Is macrophage death on the field of battle essential to victory, or a tactical weakness in immunity against tuberculosis?

Authors:  D B Lowrie
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

3.  Human Mycobacterium tuberculosis-reactive CD4+ T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes.

Authors:  W H Boom; R S Wallis; K A Chervenak
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

4.  Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254.

Authors:  J Dhillon; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis.

Authors:  D S Kumararatne; A S Pithie; P Drysdale; J S Gaston; R Kiessling; P B Iles; C J Ellis; J Innes; R Wise
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

6.  Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents.

Authors:  P W Andrew; I S Roberts
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

7.  Recombinant interleukin-2 limits the replication of Mycobacterium lepraemurium and Mycobacterium bovis BCG in mice.

Authors:  A Jeevan; G L Asherson
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

8.  Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children.

Authors:  S H Cheng; L Walker; J Poole; V R Aber; K B Walker; D A Mitchison; D B Lowrie
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

9.  Cytokine regulation of the intracellular growth of Mycobacterium paratuberculosis in bovine monocytes.

Authors:  B G Zurbrick; D M Follett; C J Czuprynski
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.